TNNT2 and COVID-19: A previous retrospective study reported that COVID-19 patients with elevated NT-proBNP (>1500 pg/mL) had a higher risk of in-hospital mortality (2.74 higher odds), and patients with low cTnT (<0.04 ng/mL) and high cTnT (≥0.04 ng/mL) exhibited an increased risk of in-hospital mortality (1.68 and 3.41 higher odds, respectively), compared to those with normal cTnT, additionally, patients with elevated levels of both cTnT and NT-proBNP had the worst outcomes, with a 6.10-fold higher risk of death 16.